Clinical trials: Lymphatic Diseases
Liver Diseases, Liver Transplant; Complications
Design and Implementation of the Pediatric Liver Transplantation Biobank
The purpose of the pediatric liver transplant biobank is to systematically collect clinical specimens from pediatric end-stage liver disease.
- Conditions
- Liver Diseases, Liver Transplant; Complications, Pediatric ALL
- Trial name
- NCT04477967
- Testing
- No intervention
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Diffuse Large B-cell Lymphoma
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to determine the efficacy and safety of ofatumomab in combination with ICE chemotherapy in subjects with relapsed/refractory DLBCL following failure to combination rituximab and anthracycline based…
- Trial name
- DLBL (NCT02412267)
- Testing
- O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
- Where
- Singapore
- Volunteers
- 17 people
- Sponsor
- National Cancer Centre, Singapore
B Cell Leukemia, B Cell Lymphoma
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells.
- Trial name
- NCT03398967
- Testing
- Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
Study of FasT CAR-T GC012F Injection NDMM Patients
This is a single-arm, single-center, open-label clinical study to evaluate the safety and efficacy of CAR-T in patients with NDMM.
- Trial name
- NCT05840107
- Testing
- GC012F injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Changzheng Hospital
Hematological Disorders
Hematology Biobank: In Vitro Study of Blood Disorders
This is a biorepository of blood specimens from subjects with different Hematological disorders.
- Trial name
- NCT02442011
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Albert Einstein College of Medicine
Breast Cancer Female, Early-stage Breast Cancer
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011…
- Conditions
- Breast Cancer Female, Early-stage Breast Cancer, Lymph Node Metastases, Axillary Metastases
- Trial name
- TADEN (NCT04671511)
- Testing
- Targeted Axillary Dissection, Ultrasound of the axilla
- Where
- 3 sites in Canada
- Volunteers
- 98 people
- Sponsor
- Jewish General Hospital
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This randomized phase II trial is comparing three different combination chemotherapy regimens to see how well they work in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00634244
- Testing
- alvocidib, mitoxantrone hydrochloride, carboplatin
- Where
- 20 sites in United States, Israel
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Plasma Cell Myeloma
Strength Training in Improving Pain and Quality of Life in Patients With Multiple Myeloma
This trial studies how well strength training works in improving bone health, pain, and quality of life in patients with multiple myeloma.
- Trial name
- NCT03793907
- Testing
- FitBit, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Roswell Park Cancer Institute
Mantle Cell Lymphoma
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
The main purpose of this study to find the ideal dose for the combination treatment of Zanubrutinib and Tafasitamab in patients with mantle cell lymphoma.
- Trial name
- ZANU-TAFA (NCT06029309)
- Testing
- Zanubrutinib, Tafasitamab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Alvaro Alencar, MD
Eosinophilic Esophagitis (EoE)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
The goal of this study is to research Dupilumab, an FDA approved medication in treating patients diagnosed with Eosinophilic esophagitis (EoE). The drug works by controlling allergic inflammation of the esophagus.
- Trial name
- NCT06665971
- Testing
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)
This open-label Phase 1 study will evaluate the safety, PK, and antitumor activity of modified T cells (JCAR017) administered to adult patients with relapsed or refractory B-cell NHL.
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle-cell Lymphoma
- Trial name
- NCT02631044
- Testing
- JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Where
- 14 sites in United States
- Volunteers
- 387 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Idiopathic Thrombocytopenia Purpura
A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability (BA) of two lots of E5501 40 mg tablets administered twice as single oral doses to healthy subjects.
- Trial name
- NCT01289509
- Testing
- E5501, Drug: E5501
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Chronic Fatigue Syndrome
A Complex Intervention for Chronically Fatigued Lymphoma Survivors
The present study is a randomized controlled trial (RCT) with an overall objective to examine the effect of an interdisciplinary complex intervention on the level of fatigue in lymphoma survivors with chronic fatigue.
- Trial name
- NCT05130099
- Testing
- Interdisciplinary complex intervention
- Where
- Norway
- Volunteers
- 150 people
- Sponsor
- Oslo University Hospital
Critical Illness, Anemia
Hemoglobin Trends as a Predictor of Outcomes in Critically Ill Patients (The TRENT-ICU Study)
The goal of this observational study is to evaluate if early absolute hemoglobin decline (during the first 24 hours of admission) can predict prolonged intensive care unit stay (8 days or more) and in-hospital mortality in…
- Trial name
- NCT07761832
- Testing
- Early Absolute Hemoglobin Decline
- Where
- Mexico
- Volunteers
- 128 people
- Sponsor
- Hospital H+ Queretaro
Sickle Cell Disease
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
Background: Sickle cell disease (SCD) is a blood disease. The drug hydroxyurea (HU) is approved to prevent pain crises in people with SCD. Researchers want to see how higher doses of HU affect the blood.
- Trial name
- NCT02225132
- Testing
- Hydroxyurea
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myasthenia Gravis, Depression
Depressive Tendency and Counseling Outcomes in Thymoma-Associated MG
This study aimed to examine whether baseline depressive tendency independently predicts post-counseling clinical outcomes in patients with thymoma-associated MG.
- Conditions
- Myasthenia Gravis, Depression, Thymoma, Depression and Quality of Life
- Trial name
- NCT07649187
- Testing
- Psychological counseling intervention
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- Ming-Hsing Chang
Lymphoma, Chemotherapy-induced Neutropenia
Danish Elder Lymphoma Patient Hematopoietic Investigation
Every year approximately 300 Danish patients die from lymphoma. The median age at diagnosis is 70 years. Lymphoma can be efficiently treated with chemotherapy, and potentially cured.
- Conditions
- Lymphoma, Chemotherapy-induced Neutropenia, Chemotherapy-Related Leukemia, Chemotherapeutic Toxicity
- Trial name
- DELPHI (NCT05245487)
- Testing
- DNA repair gene mutation analysis
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hematological Malignancies, Stem Cell Transplantation
A Prospective Registry for Febrile Events in Patients With Malignant Hemopathies or Subjected to Haematopoietic Stem Cell Transplant
Hema e-chart is an electronic case record that can be changed in real time and is based on the chronological organisation of the infective events and the therapies prescribed.
- Trial name
- HEMA E-CHART (NCT01069887)
- Where
- Italy
- Volunteers
- 3,000 people
- Sponsor
- Catholic University of the Sacred Heart
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia
- Trial name
- NCT02143414
- Testing
- Biopsy Procedure, Biospecimen Collection, Blinatumomab
- Where
- 195 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Hemophilia A
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital…
- Trial name
- ZEBRHA 2 (NCT07416604)
- Testing
- NXT007, Emicizumab
- Where
- 59 sites in United States, Argentina and 20 more
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche